Report on the second WHO integrated meeting on development and clinical trials of influenza vaccines that induce broadly protective and long-lasting immune responses: Geneva, Switzerland, 5-7 May 2014

Vaccine

Volumn 33, Issue 48, 2015, Pages 6503-6510

  Cox, Nancy J ^a   Hickling, Julian ^b   Jones, Rebecca ^b   Rimmelzwaan, Guus F ^c   Lambert, Linda C ^d   Boslego, John ^e   Rudenko, Larisa ^f   Yeolekar, Leena ^g   Robertson, James S ^h   Hombach, Joachim ⁱ   Ortiz, Justin R ⁱ  

^a NATL CENTER FOR INFECTIOUS DISEASES   (United States)

^b Working in Tandem Ltd   (United Kingdom)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^e PATH   (United States)

^f INSTITUTE OF BIOMEDICAL CHEMISTRY   (Russian Federation)

^g Serum Institute of India   (India)

^h World Health Organization ^*  (United Kingdom)

ⁱ WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VACCINE; RECOMBINANT PROTEIN; IMMUNOLOGICAL ADJUVANT; INACTIVATED VACCINE; LIVE VACCINE;

CELLULAR IMMUNITY; CONFERENCE PAPER; HUMAN; IMMUNE RESPONSE; INFLUENZA; INFLUENZA A; INFLUENZA A (H7N9); INFLUENZA VACCINATION; NONHUMAN; PANDEMIC INFLUENZA; PRIORITY JOURNAL; SEASONAL INFLUENZA; SWITZERLAND; VACCINE PRODUCTION; WORLD HEALTH ORGANIZATION; ANIMAL; CLINICAL TRIAL (TOPIC); CROSS PROTECTION; IMMUNOLOGY; INFLUENZA A VIRUS (H7N9); INFLUENZA, HUMAN; ORTHOMYXOVIRIDAE INFECTIONS; PANDEMICS; VACCINATION; VIROLOGY;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; CLINICAL TRIALS AS TOPIC; CROSS PROTECTION; HUMANS; INFLUENZA A VIRUS, H7N9 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; ORTHOMYXOVIRIDAE INFECTIONS; PANDEMICS; VACCINATION; VACCINES, ATTENUATED; VACCINES, INACTIVATED; WORLD HEALTH ORGANIZATION;

EID: 84949785121     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2015.10.014     Document Type: Conference Paper

References (72)

1. WHO Vaccines against influenza WHO position paper - November 2012. Wkly Epidemiol Rec 2012, 87:461-476.
2. Li C.K., Rappuoli R., Xu X-N. Correlates of protection against influenza virus infection in humans - on the path to a universal vaccine?. Curr Opin Immunol 2013, 25:470-476. 10.1016/j.coi.2013.07.005.
3. Girard M.P., Tam J.S., Pervikov Y., Katz J.M. Report on the first WHO integrated meeting on development and clinical trials of influenza vaccines that induce broadly protective and long-lasting immune responses: Hong Kong SAR, China, 24-26 January 2013. Vaccine 2013, 31:3766-3771. 10.1016/j.vaccine.2013.06.047.
4. Global Vaccine Action Plan Decade of vaccine collaboration. Vaccine 2013, 31(Suppl. 2):B5-B31.
5. Global Action Plan for Influenza Vaccines (GAP): [accessed 03.03.15]. http://www.who.int/influenza_vaccines_plan/en/.
6. Friede M., Palkonyay L., Alfonso C., Pervikov Y., Torelli G., Wood D., et al. WHO initiative to increase global and equitable access to influenza vaccine in the event of a pandemic: supporting developing country production capacity through technology transfer. Vaccine 2011, 29(Suppl. 1):A2-A7. 10.1016/j.vaccine.2011.02.079.
7. Partridge J., Kieny M.P. Global production capacity of seasonal influenza vaccine in 2011. Vaccine 2013, 31:728-731. 10.1016/j.vaccine.2012.10.111.
8. Cheng X., Zengel J.R., Suguitan A.L., Xu Q., Wang W., Lin J., et al. Evaluation of the humoral and cellular immune responses elicited by the live attenuated and inactivated influenza vaccines and their roles in heterologous protection in ferrets. J Infect Dis 2013, 208:594-602. 10.1093/infdis/jit207.
9. Jegaskanda S., Laurie K.L., Amarasena T.H., Winnall W.R., Kramski M., De Rose R., et al. Age-associated cross-reactive antibody-dependent cellular cytotoxicity toward 2009 pandemic influenza A virus subtype H1N1. J Infect Dis 2013, 208:1051-1061. 10.1093/infdis/jit294.
10. Jegaskanda S., Amarasena T.H., Laurie K.L., Tan H-X., Butler J., Parsons M.S., et al. Standard trivalent influenza virus protein vaccination does not prime antibody-dependent cellular cytotoxicity in macaques. J Virol 2013, 87:13706-13718. 10.1128/JVI. 01666-13.
11. Florek N.W., Weinfurter J.T., Jegaskanda S., Brewoo J.N., Powell T.D., Young G.R., et al. Modified vaccinia virus Ankara encoding influenza virus hemagglutinin induces heterosubtypic immunity in macaques. J Virol 2014, 88:13418-13428. 10.1128/JVI. 01219-14.
12. Koopmans M., de Bruin E., Godeke G.-J., Friesema I., van Gageldonk R., Schipper M., et al. Profiling of humoral immune responses to influenza viruses by using protein microarray. Clin Microbiol Infect 2012, 18:797-807. 10.1111/j.1469-0691.2011.03701.
13. Huijskens E.G.W., Reimerink J., Mulder P.G.H., van Beek J., Meijer A., de Bruin E., et al. Profiling of humoral response to influenza A(H1N1)pdm09 infection and vaccination measured by a protein microarray in persons with and without history of seasonal vaccination. PLOS ONE 2013, 8:e54890. 10.1371/journal.pone.0054890.
14. Boni M.F., Chau N.V.V., Dong N., Todd S., Nhat N.T.D., de Bruin E., et al. Population-level antibody estimates to novel influenza A/H7N9. J Infect Dis 2013, 208:554-558. 10.1093/infdis/jit224.
15. De Bruin E., Loeber J.G., Meijer A., Castillo G.M., Cepeda M.L.G., Torres-Sepúlveda M.R., et al. Evolution of an influenza pandemic in 13 countries from 5 continents monitored by protein microarray from neonatal screening bloodspots. J Clin Virol 2014, 61:74-80. 10.1016/j.jcv.2014.06.020.
16. Cheng X., Zengel J.R., Suguitan A.L., Xu Q., Wang W., Lin J., et al. Evaluation of the humoral and cellular immune responses elicited by the live attenuated and inactivated influenza vaccines and their roles in heterologous protection in ferrets. J Infect Dis 2013, 208:594-602. 10.1093/infdis/jit207.
17. Sridhar S., Begom S., Bermingham A., Hoschler K., Adamson W., Carman W., et al. Cellular immune correlates of protection against symptomatic pandemic influenza. Nat Med 2013, 19:1305-1312. 10.1038/nm.3350.
18. Wilkinson T.M., Li C.K.F., Chui C.S.C., Huang A.K.Y., Perkins M., Liebner J.C., et al. Preexisting influenza-specific CD4+ T cells correlate with disease protection against influenza challenge in humans. Nat Med 2012, 18:274-280. 10.1038/nm.2612.
19. Spensieri F., Borgogni E., Zedda L., Bardelli M., Buricchi F., Volpini G., et al. Human circulating influenza-CD4+ ICOS1+IL-21+T cells expand after vaccination, exert helper function, and predict antibody responses. Proc Natl Acad Sci U S A 2013, 110:14330-14335. 10.1073/pnas.1311998110.
20. Wagner R., Göpfert C., Hammann J., Neumann B., Wood J., Newman R., et al. Enhancing the reproducibility of serological methods used to evaluate immunogenicity of pandemic H1N1 influenza vaccines-an effective EU regulatory approach. Vaccine 2012, 30:4113-4122. 10.1016/j.vaccine.2012.02.077.
21. Consortium for the Standardization of Influenza Seroepidemiology (CONSISE) website: [accessed 03.03.15]. https://consise.tghn.org/.
22. UNISEC website. [accessed 03.03.15]. http://www.unisecconsortium.eu/.
23. Nachbagauer R., Wohlbold T.J., Hirsh A., Hai R., Sjursen H., Palese P., et al. Induction of broadly reactive anti-hemagglutinin stalk antibodies by an H5N1 vaccine in humans. J Virol 2014, 88:13260-13268. 10.1128/JVI.02133-14.
24. Khurana S., Loving C.L., Manischewitz J., King L.R., Gauger P.C., Henningson J., et al. Vaccine-induced anti-HA2 antibodies promote virus fusion and enhance influenza virus respiratory disease. Sci Transl Med 2013, 5:200ra114. 10.1126/scitranslmed.3006366.
25. Doyle T.M., Hashem A.M., Li C., Van Domselaar G., Larocque L., Wang J., et al. Universal anti-neuraminidase antibody inhibiting all influenza A subtypes. Antiviral Res 2013, 100:567-574. 10.1016/j.antiviral.2013.09.018.
26. Giles B.M., Crevar C.J., Carter D.M., Bissel S.J., Schultz-Cherry S., Wiley C.A., et al. A computationally optimized hemagglutinin virus-like particle vaccine elicits broadly reactive antibodies that protect nonhuman primates from H5N1 infection. J Infect Dis 2012, 205:1562-1570. 10.1093/infdis/jis232.
27. Gurwith M., Lock M., Taylor E.M., Ishioka G., Alexander J., Mayall T., et al. Safety and immunogenicity of an oral, replicating adenovirus serotype 4 vector vaccine for H5N1 influenza: a randomised, double-blind, placebo-controlled, phase 1 study. Lancet Infect Dis 2013, 13:238-250. 10.1016/S1473-3099(12)70345-6.
28. Peters W., Brandl J.R., Lindbloom J.D., Martinez C.J., Scallan C.D., Trager G.R., et al. Oral administration of an adenovirus vector encoding both an avian influenza A hemagglutinin and a TLR3 ligand induces antigen specific granzyme B and IFN-γ T cell responses in humans. Vaccine 2013, 31:1752-1758. 10.1016/j.vaccine.2013.01.023.
29. Antrobus R.D., Coughlan L., Berthoud T.K., Dicks M.D., Hill A.V., Lambe T., et al. Clinical assessment of a novel recombinant simian adenovirus ChAdOx1 as a vectored vaccine expressing conserved Influenza A antigens. Mol Ther 2014, 22:668-674. 10.1038/mt.2013.284.
30. Antrobus R.D., Berthoud T.K., Mullarkey C.E., Hoschler K., Coughlan L., Zambon M., et al. Coadministration of seasonal influenza vaccine and MVA-NP+M1 simultaneously achieves potent humoral and cell-mediated responses. Mol Ther 2014, 22:233-238. 10.1038/mt.2013.162.
31. Chowdhury M.Y.E., Li R., Kim J.-H., Park M.-E., Kim T.-H., Pathinayake P., et al. Mucosal vaccination with recombinant Lactobacillus casei-displayed CTA1-conjugated consensus matrix protein-2 (sM2) induces broad protection against divergent influenza subtypes in BALB/c mice. PLOS ONE 2014, 9:e94051. 10.1371/journal.pone.0094051.
32. Flugen Company website: [accessed 03.03.15]. http://www.flugen.com/.
33. Kobayashi H., Iwatsuki-Horimoto K., Kiso M., Uraki R., Ichiko Y., Takimoto T., et al. A replication-incompetent influenza virus bearing the HN glycoprotein of human parainfluenza virus as a bivalent vaccine. Vaccine 2013, 31:6239-6246. 10.1016/j.vaccine.2013.10.029.
34. Gottlieb T., Ben-Yedidia T. Epitope-based approaches to a universal influenza vaccine. J Autoimmun 2014, 54:15-20. 10.1016/j.jaut.2014.07.005.
35. Jin H., Chen Z. Production of live attenuated influenza vaccines against seasonal and potential pandemic influenza viruses. Curr Opin Virol 2014, 6C:34-39. 10.1016/j.coviro.2014.02.008.
36. Talaat K.R., Luke C.J., Khurana S., Manischewitz J., King L.R., McMahon B.A., et al. A live attenuated influenza A(H5N1) vaccine induces long-term immunity in the absence of a primary antibody response. J Infect Dis 2014, 10.1093/infdis/jiu123.
37. Ahmed S.S., Schur P.H., Macdonald N.E., Steinman L. Narcolepsy, 2009 A(H1N1) pandemic influenza, and pandemic influenza vaccinations: what is known and unknown about the neurological disorder, the role for autoimmunity, and vaccine adjuvants. J Autoimmun 2014, 50C:1-11. 10.1016/j.jaut.2014.01.033.
38. Glezen W.P. Cell-culture-derived influenza vaccine production. Lancet 2011, 377:698-700. 10.1016/S0140-6736(11)60174-8.
39. Skowronski D.M., Janjua N.Z., De Serres G., Sabaiduc S., Eshaghi A., Dickinson J.A., et al. Low 2012-13 influenza vaccine effectiveness associated with mutation in the egg-adapted H3N2 vaccine strain not antigenic drift in circulating viruses. PLOS ONE 2014, 9:e92153. 10.1371/journal.pone.0092153.
40. Huebner R.C. BARDA international and domestic capacity building activities 2013, Available at http://who.int/influenza_vaccines_plan/resources/session_6_huebner.pdf [accessed 11.02.15].
41. WHO Tables on clinical evaluation of influenza vaccines 2014, October 10, [accessed 03.03.15]. http://www.who.int/immunization/diseases/influenza/clinical_evaluation_tables/en/.
42. ®) against influenza in healthy adults: a randomized, placebo-controlled trial. Vaccine 2011, 29:7733-7739. 10.1016/j.vaccine.2011.07.128.
43. Landry N., Pillet S., Favre D., Poulin J.-F., Trépanier S., Yassine-Diab B., et al. Influenza virus-like particle vaccines made in Nicotiana benthamiana elicit durable, poly-functional and cross-reactive T cell responses to influenza HA antigens. Clin Immunol 2014, 154:164-177. 10.1016/j.clim.2014.08.003.
44. Medicago. Safety, Tolerability and Immunogenicity of a Plant-made Seasonal Quadrivalent VLP Influenza Vaccine in Adults. ClinicalTrials.gov Identifier: NCT01991587. [accessed 03.03.15]. http://clinicaltrials.gov/show/NCT01991587.
45. Fries L.F., Smith G.E., Glenn G.M. A recombinant virus-like particle influenza A (H7N9) vaccine. N Engl J Med 2013, 369:2564-2566. 10.1056/NEJMc1313186.
46. Pearton M., Pirri D., Kang S.-M., Compans R.W., Birchall J.C. Host responses in human skin after conventional intradermal injection or microneedle administration of virus-like-particle influenza vaccine. Adv Healthc Mater 2013, 2:1401-1410. 10.1002/adhm.201300006.
47. Murugappan S., Patil H.P., Frijlink H.W., Huckriede A., Hinrichs W.L.J. Simplifying influenza vaccination during pandemics: sublingual priming and intramuscular boosting of immune responses with heterologous whole inactivated influenza vaccine. AAPS J 2014, 16:342-349. 10.1208/s12248-014-9565-z.
48. Murugappan S., Patil H.P., Kanojia G., ter Veer W., Meijerhof T., Frijlink H.W., et al. Physical and immunogenic stability of spray freeze-dried influenza vaccine powder for pulmonary delivery: comparison of inulin, dextran, or a mixture of dextran and trehalose as protectants. Eur J Pharm Biopharm 2013, 85:716-725. 10.1016/j.ejpb.2013.07.018.
49. Luke C.J., Subbarao K. Improving pandemic H5N1 influenza vaccines by combining different vaccine platforms. Expert Rev Vaccines 2014, 1:11. 10.1586/14760584.2014.922416.
50. Ledgerwood J.E., Zephir K., Hu Z., Wei C.-J., Chang L., Enama M.E., et al. Prime-boost interval matters: a randomized phase 1 study to identify the minimum interval necessary to observe the H5 DNA influenza vaccine priming effect. J Infect Dis 2013, 208:418-422. 10.1093/infdis/jit180.
51. Price G.E., Lo C.-Y., Misplon J.A., Epstein S.L. Mucosal immunization with a candidate universal influenza vaccine reduces virus transmission in a mouse model. J Virol 2014, 88:6019-6030. 10.1128/JVI. 03101-13.
52. Saha S., Chadha M., Al Mamun A., Rahman M., Sturm-Ramirez K., Chittaganpitch M., et al. Influenza seasonality and vaccination timing in tropical and subtropical areas of southern and south-eastern Asia. Bull World Health Org 2014, 92:318-330. 10.2471/BLT.13.124412.
53. Nair H., Brooks W.A., Katz M., Roca A., Berkley J.A., Madhi S.A., et al. Global burden of respiratory infections due to seasonal influenza in young children: a systematic review and meta-analysis. Lancet 2011, 378:1917-1930. 10.1016/S0140-6736(11)61051-9.
54. PATH. Safety and immunogenicity of a single dose of intranasal seasonal trivalent live-attenuated influenza vaccine. ClinicalTrials.gov Identifier: NCT01625689. [accessed 03.03.15]. http://www.clinicaltrials.gov/ct2/show/NCT01625689.
55. PATH. A randomized, controlled trial on the efficacy and safety of live-attenuated influenza vaccine (LAIV) among children in Bangladesh. ClinicalTrials.gov Identifier: NCT01797029. [accessed 03.03.15]. http://www.clinicaltrials.gov/ct2/show/NCT01797029.
56. PATH. Clinical efficacy of trivalent live-attenuated influenza vaccine (LAIV) among children in Senegal. ClinicalTrials.gov Identifier: NCT01854632. [accessed 03.03.15]. http://www.clinicaltrials.gov/ct2/show/NCT01854632.
57. Dhere R., Yeolekar L., Kulkarni P., Menon R., Vaidya V., Ganguly M., et al. A pandemic influenza vaccine in India: from strain to sale within 12 months. Vaccine 2011, 29(Suppl. 1):A16-A21. 10.1016/j.vaccine.2011.04.119.
58. Biodiem Company website. [accessed 03.03.15]. http://www.biodiem.com/laiv/.
59. Lu J., Wu J., Zeng X., Guan D., Zou L., Yi L., et al. Continuing reassortment leads to the genetic diversity of Influenza H7N9 in Guangdong China. J Virol 2014, 10.1128/JVI. 00630-14.
60. Zhou J., Wang D., Gao R., Zhao B., Song J., Qi X., et al. Biological features of novel avian influenza A (H7N9) virus. Nature 2013, 499:500-503. 10.1038/nature12379.
61. Yu H., Cowling B.J., Feng L., Lau E.H.Y., Liao Q., Tsang T.K., et al. Human infection with avian influenza A H7N9 virus: an assessment of clinical severity. Lancet 2013, 382:138-145. 10.1016/S0140-6736(13)61207-6.
62. Chen Z., Baz M., Lu J., Paskel M., Santos C., Subbarao K., et al. Development of a high yield live attenuated H7N9 influenza vaccine that provides protection against homologous and heterologous H7 wild-type viruses in ferrets. J Virol 2014, 10.1128/JVI. 00100-14.
63. Rudenko L., Isakova-Sivak I., Donina S. H7N3 live attenuated influenza vaccine has a potential to protect against new H7N9 avian influenza virus. Vaccine 2013, 31:4702-4705. 10.1016/j.vaccine.2013.08.040.
64. Rudenko L., Kiseleva I., Naykhin A.N., Erofeeva M., Stukova M., Donina S., et al. Assessment of human immune responses to H7 avian influenza virus of pandemic potential: results from a placebo-controlled, randomized double-blind phase I study of live attenuated H7N3 influenza vaccine. PLOS ONE 2014, 9:e87962. 10.1371/journal.pone.0087962.
65. Dormitzer P.R., Suphaphiphat P., Gibson D.G., Wentworth D.E., Stockwell T.B., Algire M.A., et al. Synthetic generation of influenza vaccine viruses for rapid response to pandemics. Sci Transl Med 2013, 5:185ra68. 10.1126/scitranslmed.3006368.
66. Bart S.A., Hohenboken M., Della Cioppa G., Narasimhan V., Dormitzer P.R., Kanesa-Thasan N. A cell culture-derived MF59-adjuvanted pandemic A/H7N9 vaccine is immunogenic in adults. Sci Transl Med 2014, 6:234ra55. 10.1126/scitranslmed.3008761.
67. Krammer F., Cox R.J. The emergence of H7N9 viruses: a chance to redefine correlates of protection for influenza virus vaccines. Expert Rev Vaccines 2013, 12:1369-1372. 10.1586/14760584.2013.850036.
68. Krammer F., Jul-Larsen A., Margine I., Hirsh A., Sjursen H., Zambon M., et al. An H7N1 influenza virus vaccine induces broadly reactive antibody responses against H7N9 in humans. Clin Vaccine Immunol 2014, 10.1128/CVI.00272-14.
69. Chit A., Parker J., Halperin S.A., Papadimitropoulos M., Krahn M., Grootendorst P. Toward more specific and transparent research and development costs: the case of seasonal influenza vaccines. Vaccine 2014, 32:3336-3340. 10.1016/j.vaccine.2013.06.055.
70. Jain V.K., Rivera L., Zaman K., Espos R.A., Sirivichayakul C., Quiambao B.P., et al. Vaccine for prevention of mild and moderate-to-severe influenza in children. N Engl J Med 2013, 369:2481-2491. 10.1056/NEJMoa1215817.
71. European Medicines Agency, Committee for Medicinal Products for Human Use Guideline on influenza vaccines - quality module 2014, April 25, Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2014/06/WC500167817.pdf [accessed 03.03.15].
72. WHO. Second WHO integrated meeting on development and clinical trials of Influenza vaccines that induce broadly protective and long-lasting immune responses. [accessed 03.03.15]. http://www.who.int/immunization/research/meetings_workshops/2nd_influenzamtg_geneva_may14/en/.